Denali Therapeutics Inc. (DNLI) Stock Analysis
A live, multi-source view of Denali Therapeutics Inc. (DNLI): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Sector: Healthcare · Industry: Biotechnology · United States · 503 employees · denalitherapeutics.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Denali Therapeutics Inc. (DNLI) had a market capitalization of $3.56B (forward -9.2) and a beta of 1.00; the shares traded in a 52-week range of $12.58 – $27.30 (47.1% over the year).
- Market cap
- $3.56B
- Enterprise value
- $2.89B
- Forward P/E
- -9.2
- Price / book
- 4.26
- EPS (trailing)
- $-2.84
- EPS (forward)
- $-2.43
- Payout ratio
- 0.0%
- 52-week range
- $12.58 – $27.30
- 52-week change
- 47.1%
- Beta
- 1.00
- Average volume
- 1.7M
- Shares outstanding
- 159.8M
- Short % of float
- 11.85%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-08
In RapidTradeView’s 2026-09-08 scan of the US universe, Denali Therapeutics Inc. (DNLI) last closed at $22.28 (the last completed close before that scan).
Technicals at the scan: RSI 35 (neutral territory), price -8.3% versus its 20-day average, 20-day versus 50-day average spread -0.6%, MACD histogram -0.29.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 76/100.
Next scheduled company event: in 58 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for DNLI in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
DNLI has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Denali Therapeutics Inc. (DNLI) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell DNLI.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.